Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$4.68M | -$12.6M | -$11.6M |
| Net income | -$5.11M | -$16.5M | -$11.9M |
| EPS (diluted) | $44.23 | $394.94 | $8.96 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$4.53M | -$8.40M | -$10.8M |
| Capital expenditures | $12.0K | $22.0K | $9.00K |
| Free cash flow | -$4.54M | -$8.42M | -$10.8M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $4.59M | $1.19M | $5.99M |
| Total assets | $5.26M | $2.86M | $7.21M |
| Total liabilities | $2.25M | $6.85M | $4.61M |
| Shareholders' equity | -$15.5M | -$3.99M | $2.60M |
| Retained earnings | -$26.8M | -$43.3M | -$55.2M |
| Shares (wtd avg diluted) | 112K | 41.6B | 1.33M |
Every figure is extracted from Silexion Therapeutics Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.